Table I.

Select patient characteristics and histologic quantitationa

HealthyRA: MTXRA: Anti-TNF
HAQ (0–3)0.24 (0.22)0.3 (0.47)
DAS (0–9.3)3.69 (1.0)3.3 (1.3)
RF+ (%)77%79%
GC (Bm3/4)33 ± 1227 ± 1813 ± 9b
FDC (%)12.2 ± 4.811.9 ± 5.17.5 ± 1.6c
FDC/IgD0.63 ± 0.290.71 ± 0.100.42 ± 0.14d
GC (%)8.4 ± 3.69 ± 5.22.3 ± 1.6e
1°:2°2.8:13.21:144.7:7.3
  • a The first three rows from the top summarize select patient characteristics (HAQ, health assessment questionnaire; DAS, disease activity score) with mean ± SD or positive percentage (RF, rheumatoid factor) in RA on MTX (n = 17) and RA on anti-TNF (n = 28) recruited for PB analysis. The next four rows characterize tonsil tissue from healthy subjects (n = 25 for flow cytometry analysis of GC cells), RA on MTX (n = 2), and RA on anti-TNF (n = 4). FDC network area is quantitated as a percentage of the total tissue area (FDC (%)) or relative to the IgD+ areas (FDC/IgD) and is based on morphometric analysis of immunohistochemistry stains. The fraction of the total tissue area occupied by GC FDC networks (GC (%)) and the mean primary number (1°) to secondary follicle number (2°) are shown. The statistical significance of the differences is indicated as follows:

  • b p = 0.003 compared to healthy controls;

  • c p = 0.036 compared to healthy controls;

  • d p < 0.0001 compared to RA MTX; and

  • e p < 0.0001 compared to RA MTX and healthy controls.